Physician profile
Young Lee
NPI 1831249465
$1,996.53
in general payments reported to CMS, 2019-2025
26 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2021: $16.51 · 2022: $91.36 · 2023: $587 · 2024: $362 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.67 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.85 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $169.30 | 2023-2025 | Rebyota |
| Pfizer INC. | $136.90 | 2023-2025 | |
| Saluda Medical Americas, INC. | $136.23 | 2025 | Evoke |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Madrigal Pharmaceuticals | $116.39 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $112.57 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $75.31 | 2025 | Iqirvo |
| Lilly USA, LLC | $71.78 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $70.86 | 2023-2025 | Stelara, Tremfya |
| Intuitive Surgical, INC. | $48.29 | 2024 | |
| Gilead Sciences, INC. | $40.92 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $39.31 | 2023-2024 | Dupixent |
| Azurity Pharmaceuticals, INC. | $33.59 | 2025 | Danziten |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $33.22 | 2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $28.31 | 2025 | |
| Braintree Laboratories, INC. | $24.77 | 2023 | Sutab |
| Celltrion USA INC. | $24.35 | 2025 | Vegzelma |
| Cook Medical LLC | $23.67 | 2022 | |
| Indivior INC. | $22.32 | 2019 | |
| Genzyme Corporation | $20.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.98 | 2025 | Xifaxan |
| Capsovision, INC. | $15.27 | 2025 | Capsocam Plus |
| Echosens North America, INC. | $10.50 | 2023 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $7.73 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.